Several clinical studies [38, 39] have demonstrated that the tyrosine kinase receptor inhibitor Nintedanib is a secure and proficient treatment for IPF patients by diminishing the FVC decline rate. Here, NTRK1 is linked to idiopathic interstitial pneumonia.